Autres langues Amylyx Pharmaceuticals, Inc.

Actions

AMLX

US03237H1014

Marché Fermé - Nasdaq Autres places de cotation 21:59:52 03/05/2024			Varia. 5j.	Varia. 1 janv.
2,04 ^USD	+2,00%		+15,91%	-86,14%

11/04	AMYLYX PHARMACEUTICALS, INC. : Baird neutre sur le dossier	ZM
10/04	Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024	02/05
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome	10/04
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome	10/04
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX	09/04
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)	08/04
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024	08/04
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders	08/04
AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX	06/04
AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit	05/04
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO, ALBRIOZA from the Market, Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy	05/04
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX	05/04
AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX	04/04
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX	04/04
Sector Update: Health Care Stocks Mixed in Afternoon Trading	04/04
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio	04/04
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx	04/04
Amylyx Pharmaceuticals Pulling ALS Drug, Cutting Staff by 70%	04/04
Amylyx Pharmaceuticals to Discontinue Relyvrio/Albrioza in US, Canada; Slashes Workforce by 70%	04/04
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market	04/04
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy	04/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Amylyx Pharmaceuticals, Inc.

Actions

AMLX

US03237H1014

Autres langues

Filtres